Caplin Point Laboratories Ltd
NSE:CAPLIPOINT

Watchlist Manager
Caplin Point Laboratories Ltd Logo
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Watchlist
Price: 2 600.15 INR 8.38% Market Closed
Market Cap: 197.6B INR
Have any thoughts about
Caplin Point Laboratories Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one CAPLIPOINT stock under the Base Case scenario is 1 551.53 INR. Compared to the current market price of 2 600.15 INR, Caplin Point Laboratories Ltd is Overvalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAPLIPOINT Relative Value
Base Case
1 551.53 INR
Overvaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10.8
P/S
P/S
Price to Sales
10.8
vs History
4
vs Industry
20
Median 3Y
5
Median 5Y
4.2
Industry
2.5
Forward
10
More Details
40
P/E
P/E
Price to Earnings
40
vs History
4
vs Industry
19
Median 3Y
20.1
Median 5Y
17.8
Industry
21.8
Forward
37.6
More Details
52.7
P/OCF
P/OCF
Price to OCF
52.7
vs History
17
vs Industry
12
Median 3Y
29.5
Median 5Y
22.6
Industry
16.1
More Details
86.2
P/FCFE
P/FCFE
Price to FCFE
86.2
vs History
23
vs Industry
8
Median 3Y
61
Median 5Y
28.4
Industry
23.8
More Details
7.8
P/B
P/B
Price to Book Value
7.8
vs History
4
vs Industry
15
Median 3Y
4.2
Median 5Y
3.8
Industry
2.1
More Details
10.3
EV/S
EV/S
Enterprise Value to Sales
10.3
vs History
4
vs Industry
20
Median 3Y
4.5
Median 5Y
3.7
Industry
2.6
Forward
9.6
More Details
17.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
17.6
vs History
4
vs Industry
18
Median 3Y
8
Median 5Y
7
Industry
5.2
More Details
31.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.3
vs History
4
vs Industry
19
Median 3Y
14.3
Median 5Y
12.3
Industry
13.8
Forward
28.7
More Details
34.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
34.9
vs History
4
vs Industry
20
Median 3Y
15.8
Median 5Y
13.8
Industry
17
Forward
27.9
More Details
50.4
EV/OCF
EV/OCF
Enterprise Value to OCF
50.4
vs History
17
vs Industry
13
Median 3Y
26.8
Median 5Y
20
Industry
15.3
More Details
81.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
81.8
vs History
22
vs Industry
7
Median 3Y
54.9
Median 5Y
23.1
Industry
19.2
More Details
10.3
EV/IC
EV/IC
Enterprise Value to IC
10.3
vs History
6
vs Industry
15
Median 3Y
5.7
Median 5Y
4.9
Industry
1.9
More Details

Multiples Across Competitors

CAPLIPOINT Competitors Multiples
Caplin Point Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
197.6B INR 10.8 40 31.3 34.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
743.9B USD 18.2 88.9 47.8 53.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 10.4 29.7 20.6 23.5
US
Johnson & Johnson
NYSE:JNJ
349.2B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
252.4B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
202.2B CHF 3.4 17.6 9.9 11.8
UK
AstraZeneca PLC
LSE:AZN
162.2B GBP 4.2 31.7 169.4 253.9
CH
Novartis AG
SIX:NOVN
173.8B CHF 3.9 10.9 9.5 13.2
US
Pfizer Inc
NYSE:PFE
150.9B USD 2.5 35.5 10.6 15.9
P/E Multiple
Earnings Growth PEG
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Average P/E: 33.2
40
17%
2.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
88.9
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29.7
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
17.6
15%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.7
40%
0.8
CH
Novartis AG
SIX:NOVN
10.9
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.5
102%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Average EV/EBITDA: 416.7
31.3
17%
1.8
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
43%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.6
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.5
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
UK
AstraZeneca PLC
LSE:AZN
169.4
18%
9.4
CH
Novartis AG
SIX:NOVN
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Average EV/EBIT: 1 813.6
34.9
20%
1.7
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
46%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.5
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
15
9%
1.7
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
11.8
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
253.9
32%
7.9
CH
Novartis AG
SIX:NOVN
13.2
17%
0.8
US
Pfizer Inc
NYSE:PFE
15.9
19%
0.8

See Also

Summary
CAPLIPOINT intrinsic value, competitors valuation, and company profile.
DCF Valuation
CAPLIPOINT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CAPLIPOINT stock valuation using valuation multiples.
Wall Street Estimates
CAPLIPOINT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CAPLIPOINT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.